Cyclophosphamide (CyP) is the immunosuppressive agent of choice in ocular mucous membrane pemphigoid (MMP). However, guidelines do not specify the regimen modality of CyP treatment. We introduce our practical management protocol for ocular MMP using fixed low-dose intravenous (IV) pulses of CyP followed by IV rituximab, accompanied by case studies of two elderly patients who achieved complete and enduring remissions without adverse effects.
No takes yet. Share an insight, caveat, or question.
Viedma‐Martínez et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: